Literature DB >> 23661021

MMP-2 -1306C>T polymorphism in breast cancer: a case-control study in a South European population.

Flora Zagouri1, Theodoros N Sergentanis, Maria Gazouli, Constantine Dimitrakakis, Alexandra Tsigginou, Irene Papaspyrou, Dimosthenis Chrysikos, Maria Lymperi, George C Zografos, Aris Antsaklis, Meletios-Athanassios Dimopoulos, Christos A Papadimitriou.   

Abstract

This case control study aims to investigate the role of MMP-2 -1306C>T polymorphism as a potential risk factor and possible prognostic marker for breast cancer in a South European population. 113 consecutive incident cases of histologically confirmed ductal breast cancer and 124 healthy controls were recruited. MMP-2 -1306C>T polymorphism was genotyped; multivariate logistic regression as well as Cox regression analysis were performed. MMP-2 -1306C>T status was not associated with breast cancer risk either at the total sample or at the subanalyses on premenopausal and postmenopausal women. At the survival analysis, a trend towards a favorable association between MMP-2 -1306C>T allele and disease-free survival as well as overall survival was observed. Regarding subanalyses on ER-negative and ER-positive cases, the favorable association implicating MMP-2 -1306C>T allele was particularly evident among ER-positive cases; no significant associations emerged among ER-negative cases. MMP-2 -1306C>T polymorphism does not seem to be a risk factor for breast cancer in South European population; however, a trend towards a favorable association with survival has been observed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23661021     DOI: 10.1007/s11033-013-2604-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  19 in total

Review 1.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

2.  Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression.

Authors:  Haixin Lei; Kari Hemminki; Andrea Altieri; Robert Johansson; Kerstin Enquist; Göran Hallmans; Per Lenner; Asta Försti
Journal:  Breast Cancer Res Treat       Date:  2006-10-11       Impact factor: 4.872

3.  Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study.

Authors:  O Brummer; S Athar; L Riethdorf; T Löning; H Herbst
Journal:  Virchows Arch       Date:  1999-12       Impact factor: 4.064

4.  Serum MMPs and TIMPs: may be predictors of breast carcinogenesis?

Authors:  Flora Zagouri; Theodoros N Sergentanis; Elena Kalogera; Xeni Provatopoulou; Dimosthenis Chrysikos; Eleni Zografos; Garifallia Bletsa; Ioannis Flessas; Christos A Papadimitriou; George C Zografos; Antonia Gounaris
Journal:  Clin Chim Acta       Date:  2010-12-03       Impact factor: 3.786

5.  Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation.

Authors:  S J Price; D R Greaves; H Watkins
Journal:  J Biol Chem       Date:  2000-12-12       Impact factor: 5.157

6.  Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer.

Authors:  Chunyuan Yu; Yifeng Zhou; Xiaoping Miao; Ping Xiong; Wen Tan; Dongxin Lin
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

7.  Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies.

Authors:  Dai-Hua Fang; Cong-Hai Fan; Qiang Ji; Bo-Xiang Qi; Juan Li; Lu Wang
Journal:  Mol Biol Rep       Date:  2012-02-10       Impact factor: 2.316

8.  HTERT MNS16A polymorphism in breast cancer: a case-control study.

Authors:  Flora Zagouri; Theodoros N Sergentanis; Maria Gazouli; Alexandra Tsigginou; Constantine Dimitrakakis; Evaggelos Eleutherakis-Papaiakovou; Irene Papaspyrou; Dimosthenis Chrysikos; George Theodoropoulos; George C Zografos; Aris Antsaklis; Athanassios-Meletios Dimopoulos; Christos A Papadimitriou
Journal:  Mol Biol Rep       Date:  2012-10-12       Impact factor: 2.316

9.  Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility.

Authors:  Alicia Beeghly-Fadiel; Wei Lu; Ji-Rong Long; Xiao-ou Shu; Ying Zheng; Qiuyin Cai; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05-19       Impact factor: 4.254

10.  Expression of proteinases and inhibitors in human breast cancer progression and survival.

Authors:  E A Baker; T J Stephenson; M W R Reed; N J Brown
Journal:  Mol Pathol       Date:  2002-10
View more
  2 in total

1.  Prognostic impact of polymorphism of matrix metalloproteinase-2 and metalloproteinase tissue inhibitor-2 promoters in breast cancer in Tunisia: case-control study.

Authors:  Dalel Ben Néjima; Yosr Ben Zarkouna; Amor Gammoudi; Mohamed Manai; Hamouda Boussen
Journal:  Tumour Biol       Date:  2015-02-06

2.  Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population.

Authors:  Katarzyna Białkowska; Wojciech Marciniak; Magdalena Muszyńska; Piotr Baszuk; Satish Gupta; Katarzyna Jaworska-Bieniek; Grzegorz Sukiennicki; Katarzyna Durda; Tomasz Gromowski; Marcin Lener; Karolina Prajzendanc; Alicja Łukomska; Cezary Cybulski; Tomasz Huzarski; Jacek Gronwald; Tadeusz Dębniak; Jan Lubiński; Anna Jakubowska
Journal:  Hered Cancer Clin Pract       Date:  2020-07-31       Impact factor: 2.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.